[HTML][HTML] Alzheimer's disease: epidemiology and clinical progression

AA Tahami Monfared, MJ Byrnes, LA White… - Neurology and …, 2022 - Springer
Alzheimer's disease (AD) is prevalent throughout the world and is the leading cause of
dementia in older individuals (aged≥ 65 years). To gain a deeper understanding of the …

Assessing the mechanisms of brain plasticity by transcranial magnetic stimulation

A Jannati, LM Oberman, A Rotenberg… - …, 2023 - nature.com
Transcranial magnetic stimulation (TMS) is a non-invasive technique for focal brain
stimulation based on electromagnetic induction where a fluctuating magnetic field induces a …

Global estimates on the number of persons across the Alzheimer's disease continuum

A Gustavsson, N Norton, T Fast, L Frölich… - Alzheimer's & …, 2023 - Wiley Online Library
Introduction Global estimates on numbers of persons in early stages of Alzheimer's disease
(AD), including prodromal and preclinical, are lacking, yet are needed to inform policy …

[HTML][HTML] NIA-AA research framework: toward a biological definition of Alzheimer's disease

CR Jack Jr, DA Bennett, K Blennow, MC Carrillo… - Alzheimer's & …, 2018 - Elsevier
Abstract In 2011, the National Institute on Aging and Alzheimer's Association created
separate diagnostic recommendations for the preclinical, mild cognitive impairment, and …

Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype

L Vermunt, SAM Sikkes, A Van Den Hout… - Alzheimer's & …, 2019 - Elsevier
Introduction We estimated the age-specific duration of the preclinical, prodromal, and
dementia stages of Alzheimer's disease (AD) and the influence of sex, setting …

A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers

CR Jack Jr, DA Bennett, K Blennow, MC Carrillo… - Neurology, 2016 - AAN Enterprises
Biomarkers have become an essential component of Alzheimer disease (AD) research and
because of the pervasiveness of AD pathology in the elderly, the same biomarkers are used …

Alzheimer's disease

P Scheltens, K Blennow, MMB Breteler, B De Strooper… - The Lancet, 2016 - thelancet.com
Although the prevalence of dementia continues to increase worldwide, incidence in the
western world might have decreased as a result of better vascular care and improved brain …

Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative

DP Veitch, MW Weiner, PS Aisen, LA Beckett… - Alzheimer's & …, 2019 - Elsevier
Introduction The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to
validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI is a multisite …

Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States

R Brookmeyer, N Abdalla, CH Kawas… - Alzheimer's & Dementia, 2018 - Elsevier
Introduction We forecast the prevalence of preclinical and clinical Alzheimer's disease (AD)
and evaluated potential impacts of primary and secondary preventions in the United States …

Alzheimer disease

DS Knopman, H Amieva, RC Petersen… - Nature reviews Disease …, 2021 - nature.com
Alzheimer disease (AD) is biologically defined by the presence of β-amyloid-containing
plaques and tau-containing neurofibrillary tangles. AD is a genetic and sporadic …